The observed upregulation of expression of CD73TC at baseline, along with its association with a longer EFS and lower expression of PD-L1, highlights its potential importance in the evolving landscape of immunotherapy and targeted treatments for EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.